Logo

Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

Share this

Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

Shots:

  • In a post-hoc- sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD with motor fluctuations
  • The new P-III post-hoc sub-group analysis demonstrated that long-term treatment with Ongentys when used as an add-on therapy reduced "On" time with troublesome dyskinesia and increased good "On" time without troublesome dyskinesia in patients with PD with motor fluctuations
  • Long term use of therapy leads to a reduction in the patient's average daily levodopa dosage requirement. Ongentys (qd- PO) is a selective and reversible COMT inhibitor and has received the US FDA’s approval as an add-on treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes

     ­ Ref: PRN | Image: Neurocrine


Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions